| 前收盘价格 | 46.13 |
| 收盘价格 | 45.66 |
| 成交量 | 502,642 |
| 平均成交量 (3个月) | 749,801 |
| 市值 | 2,485,281,536 |
| 预期市盈率 (P/E Forward) | 22.12 |
| 价格/销量 (P/S) | 1.89 |
| 股市价格/股市净资产 (P/B) | 2.32 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2025 |
| 营业毛利率 | -17.42% |
| 营业利益率 (TTM) | 15.54% |
| 稀释每股收益 (EPS TTM) | -4.07 |
| 季度收入增长率 (YOY) | 7.40% |
| 季度盈利增长率 (YOY) | 242.10% |
| 总债务/股东权益 (D/E MRQ) | 65.54% |
| 流动比率 (MRQ) | 1.58 |
| 营业现金流 (OCF TTM) | 197.02 M |
| 杠杆自由现金流 (LFCF TTM) | 782.12 M |
| 资产报酬率 (ROA TTM) | 4.55% |
| 股东权益报酬率 (ROE TTM) | -19.70% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | LivaNova PLC | 看涨 | 看跌 |
AIStockmoo 评分
-0.3
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -4.0 |
| 平均 | -0.25 |
|
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Core |
| 内部持股比例 | 0.38% |
| 机构持股比例 | 102.95% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 64.00 (Needham, 40.41%) | 购买 |
| 中 | 62.00 (36.03%) | |
| 低 | 60.00 (Wolfe Research, 31.64%) | 购买 |
| 平均值 | 62.00 (36.03%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 44.47 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wolfe Research | 20 May 2025 | 60.00 (31.64%) | 购买 | 44.88 |
| Needham | 13 May 2025 | 64.00 (40.41%) | 购买 | 44.06 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合